Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study
Publication
, Journal Article
Farahany, NA; Benatar, M; Wuu, J; Andersen, PM; Bucelli, RC; Andrews, JA; Otto, M
Published in: Neurotherapeutics
2022
Duke Scholars
Published In
Neurotherapeutics
Publication Date
2022
Volume
19
Issue
4
Start / End Page
1248 / 1258
Related Subject Headings
- Superoxide Dismutase-1
- Superoxide Dismutase
- RNA, Messenger
- Oligonucleotides, Antisense
- Neurology & Neurosurgery
- Neurodegenerative Diseases
- Mutation
- Humans
- Biomarkers
- Amyotrophic Lateral Sclerosis
Citation
APA
Chicago
ICMJE
MLA
NLM
Farahany, N. A., Benatar, M., Wuu, J., Andersen, P. M., Bucelli, R. C., Andrews, J. A., & Otto, M. (2022). Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics, 19(4), 1248–1258.
Farahany, Nita A., Michael Benatar, Joanne Wuu, Peter M. Andersen, Robert C. Bucelli, Jinsy A. Andrews, and Markus Otto. “Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.” Neurotherapeutics 19, no. 4 (2022): 1248–58.
Farahany NA, Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, et al. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. 2022;19(4):1248–58.
Farahany, Nita A., et al. “Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.” Neurotherapeutics, vol. 19, no. 4, 2022, pp. 1248–58.
Farahany NA, Benatar M, Wuu J, Andersen PM, Bucelli RC, Andrews JA, Otto M. Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study. Neurotherapeutics. 2022;19(4):1248–1258.
Published In
Neurotherapeutics
Publication Date
2022
Volume
19
Issue
4
Start / End Page
1248 / 1258
Related Subject Headings
- Superoxide Dismutase-1
- Superoxide Dismutase
- RNA, Messenger
- Oligonucleotides, Antisense
- Neurology & Neurosurgery
- Neurodegenerative Diseases
- Mutation
- Humans
- Biomarkers
- Amyotrophic Lateral Sclerosis